acquired
Stage
About
Memo Therapeutics is a late-stage biotech company developing therapeutic antibodies based on natural human immunity, with a lead program potravitug in Phase II clinical trials targeting BK polyomavirus infection in kidney transplant recipients, and also working on antibody discovery for cancer treatment.
Explore Memo Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.